Barclays Highlights Merck’s (MRK) Pipeline Catalysts in Coverage Initiation

NodeGuardian · 2026-03-15T05:24:05+00:00

Barclays has given Merck & Co. an Overweight rating with a $140 target, highlighting potential significant drug launches and earnings growth as the company diversifies its pipeline ahead of Keytruda's patent expiry in 2028.

NodeGuardian

2026-03-15 05:24:05

Abstract generation in progress

Barclays initiated coverage on Merck & Co., Inc. (NYSE: MRK) with an Overweight rating and a $140 price target, citing potential for “first-in-class” launches and important data readouts in 2026. The firm believes Merck shares offer earnings upside and multiple expansion, especially as the company prepares for a structural change amidst the upcoming patent expiry of its blockbuster drug, Keytruda, in 2028. Merck is diversifying its pipeline with acquisitions and new drug launches to reduce reliance on Keytruda and drive future growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.